Core Viewpoint - The company expects significant revenue growth and a turnaround in profitability for the fiscal year ending December 31, 2025, driven by new product launches and market share gains in the ischemic stroke segment [1] Revenue Forecast - The company anticipates revenue between approximately RMB 400 million and RMB 410 million for the fiscal year ending December 31, 2025, representing an increase of at least 43.9% compared to the revenue of RMB 278 million for the fiscal year ending December 31, 2024 [1] Profitability Outlook - The company projects a pre-tax profit of approximately RMB 80 million for the reporting period, a significant improvement compared to a pre-tax net loss of RMB 12 million for the fiscal year ending December 31, 2024 [1] Growth Drivers - Revenue growth is driven by several factors, including the launch of new products and technologies for ischemic stroke, increased market share in ischemic stroke products, commercialization of intracranial stents, rising sales of other hemorrhagic stroke products, and sustained growth in interventional access product sales [1] - The company has also implemented effective cost control measures, reducing the expense ratio through lower sales costs and administrative expenses [1]
心玮医疗-B(06609)发盈喜 预期2025年收益约4亿元至4.1亿元 同比增加至少43.9%